Help
Subscribe


All of GastroHep is now free access! - Click here to register Read For FREE - Our full range of review articles
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Guido Tytgat Profile of Pete Peterson Profile of Peter Cotton Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Proposed cut-off values for the enhanced liver fibrosis score

A study in the most recent issue of the Journal of Hepatology evaluates normal values, influence factors and proposed cut-off values of the Enhance Liver Fibrosis score.

News image

Progressive fibrosis is a major cause of morbidity and mortality in chronic liver disease.

To replace liver biopsy for disease staging, multiple serum markers are under evaluation with multiparametric panels yielding the most promising results.

The Enhanced Liver Fibrosis score is an ECM marker set consisting of tissue inhibitor of metalloproteinases, amino-terminalpropeptide of type III procollagen and hyaluronic acid showing good correlations with fibrosis stages in chronic liver disease.

Dr Ralf Lichtinghagen and colleagues from Germany measured the Enhanced Liver Fibrosis score in 400 healthy controls, and 79 chronic Hepatitis C patients using an ADVIA Centaur automated system.

The Enhanced Liver Fibrosis score was calculated using the published algorithm combining TIMP-1, amino-terminalpropeptide of type III procollagen and hyaluronic acid values.

Patients’ fibrosis stage was defined histologically.

Age was a notable influence factor
Journal of Hepatology

ROC analyses were performed to study marker validity.

Reference values and influence factors for the Enhanced Liver Fibrosis score were validated.

Enhanced Liver Fibrosis score reference values ranged from about 7 to 10, and were significantly higher for men vs. women.

The team observed that afternoon values were slightly higher than morning values.

The research team found that age was a notable influence factor.

The doctors identified 3 cut-off values, including 7.7 for a high sensitivity exclusion of fibrosis, 9.8 for a high specificity identification of fibrosis, and 11.3 to discriminate cirrhosis.

The team noted that the Enhanced Liver Fibrosis score validity was superior to the results of the single tests.

Dr Lichtinghagen's team concludes, "The Enhanced Liver Fibrosis score can predict moderate fibrosis and cirrhosis."

"However, influence factors such as gender and age need to be taken into account."

J Hepatology 2013: 59(2): 236-242
06 August 2013

Go to top of page Email this page Email this page to a colleague

 01 August 2014

Advanced search
 01 August 2014 
Fully covered self-expanding metal stents for benign biliary strictures
 01 August 2014 
Capsule colonoscopy vs CT colonography for polyp screening
 01 August 2014 
Complications after obesity surgery
 31 July 2014 
Biomarkers in liver fibrosis
 31 July 2014 
Risk factors of large colorectal polyps
 31 July 2014 
Diverticular disease and colon cancer
 30 July 2014 
Interval between screening colonoscopies
 30 July 2014 
Small intestinal permeability in diarrhea predominant IBS
 30 July 2014 
Mineral rich water and constipation
 29 July 2014 
Fluticasone in eosinophilic esophagitis
 29 July 2014 
Causes of GI bleeding in cirrhosis
 29 July 2014 
ALT increases in Hep B
 28 July 2014 
Statins reduce Barrett's
 28 July 2014 
Score predicts risk for Barrett’s esophagus
 28 July 2014 
Gastric cancer prevention
 25 July 2014 
De-escalation of therapy in IBD
 25 July 2014 
Bionic pancreas in type 1 diabetes
 25 July 2014 
Primary care physician counselling and colonoscopy
 24 July 2014 
Diagnostic tool for obscure-overt GI bleeding
 24 July 2014 
Statin use and Barrett’s esophagus
 24 July 2014 
Atopy and functional GI disorders
 23 July 2014 
Sofosbuvir and ribavirin for Hep C
 23 July 2014 
Early corticosteroids after the diagnosis of ulcerative colitis
 23 July 2014 
C-section and IBD risk
 22 July 2014 
Thromboembolism in IBD
 22 July 2014 
Alcohol and colorectal adenoma risk
 22 July 2014 
Cognitive behavioral therapy in IBS
 21 July 2014 
Stents to prevent post-ERCP pancreatitis
 21 July 2014 
Psychometric validation of IBS symptom severity
 21 July 2014 
Mortality in IBD
 18 July 2014 
Treatment of enteropancreatic neuroendocrine tumors
 18 July 2014 
Ulcer complications and dyspeptic symptoms
 18 July 2014 
ERCP with overtube-assisted enteroscopy
 17 July 2014 
Treatment of H. pylori
 17 July 2014 
Ultrasound for diagnosis of gastric varices
 17 July 2014 
Small intestinal permeability in diarrhea predominant IBS
 16 July 2014 
Mortality after colectomy in IBD
 16 July 2014 
Esophageal cancer missed at endoscopy
 16 July 2014 
Screening for Hepatitis B
 15 July 2014 
Diagnosing diverticulitis
 15 July 2014 
Variation in management decisions for colorectal cancer
 15 July 2014 
Muscle cramps in cirrhosis
 14 July 2014 
Predicting the course of ulcerative colitis
 14 July 2014 
Choice in colorectal cancer screening tests
 14 July 2014 
Adhesions in abdominal surgery
 11 July 2014 
Temporal evolution of antidrug antibodies in IBD
 11 July 2014 
Atopy and functional gastrointestinal disorders
 11 July 2014 
Fecal microbiota transplant for C. diff
 10 July 2014 
Acid-suppressive medications and cancer risk in Barrett's
 10 July 2014 
Personalized medicine in the management of IBD
 10 July 2014 
Pregnancy outcome in anti-TNF treated women with IBD
 09 July 2014 
Quality of care provided to patients with varices
 09 July 2014 
Eosinophilic esophagitis and celiac disease
 09 July 2014 
Diagnosis and management of adult celiac disease
 08 July 2014 
Screening for Hep B
 08 July 2014 
NSAID-induced small intestinal injury
 08 July 2014 
Drug-induced liver injury
 07 July 2014 
Obesity and complications after lapaproscopic colorectal surgery
 07 July 2014 
Everolimus and advanced hepatocellular carcinoma
 07 July 2014 
Pediatric celiac disease risk factors

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2014 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us